Stocktoria
Erasca, Inc. ERAS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-07-15
Erasca, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$140.9M | -$179.6M | -$141.5M | -$247.4M | -$124.9M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$124.5M | -$161.7M | -$125.0M | -$242.8M | -$122.8M |
| EPS (diluted) | $-0.44 | $-0.69 | $-0.83 | $-1.99 | $-1.85 |
| Operating cash flow | -$95.5M | -$109.4M | -$101.2M | -$103.3M | -$79.6M |
| Free cash flow | -$95.6M | -$109.5M | -$103.0M | -$117.8M | -$90.8M |
| Cash & equivalents | $73.8M | $67.7M | $93.1M | $284.2M | $360.5M |
| Total assets | $396.2M | $502.5M | $395.3M | $514.9M | $501.4M |
| Total liabilities | $71.0M | $79.0M | $78.6M | $103.1M | $44.9M |
| Shareholders' equity | $325.2M | $423.5M | $316.7M | $411.9M | $456.5M |
Source: SEC EDGAR filings · CIK 0001761918 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.